Skip to main content

Advertisement

Table 2 Characteristics of patients with or without renal dysfunction

From: Plasma tenofovir trough concentrations are associated with renal dysfunction in Japanese patients with HIV infection: a retrospective cohort study

  Renal dysfunction patients N = 7 Non-renal dysfunction patients N = 4 p value
Age (years) a 45.0 (38.0–52.0) 29.5 (24.0–35.8) 0.072
Body weight (kg) a 52.2 (49.4–62.9) 60.8 (59.0–68.8) 0.078
BMI (kg/m2) a 17.7 (17.2–20.9) 21.3 (20.2–23.8) 0.078
BSA (m2) a 1.60 (1.57–1.77) 1.70 (1.69–1.79) 0.169
Serum creatinine (mg/dL) a 0.70 (0.65–0.80) 0.80 (0.78–0.83) 0.163
eGFR (mL/min · 1.73 m2) a 96.1 (85.9–102.9) 90.4 (82.7–104.2) 0.925
Rate of decrease in eGFR (%) a 33.2 (24.3–38.2) 11.7 (8.0–12.9) 0.008
CD4+ cell count (/μL) a 58 (36–133) 204 (99–320) 0.149
HIV RNA viral load (log10/mL) a 4.63 (4.52–5.84) 5.33 (4.82–5.92) 0.395
Protease inhibitors (ritonavir-boosted), n (%) 4 (57.1) 3 (75.0) 1.000
INSTIs, n (%) 3 (42.9) 1 (25.0) 1.000
Concurrent use of a nephrotoxic drug, n (%) 2 (28.6) 2 (50) 0.576
Hepatitis B, n (%) 3 (42.6) 0 (0) 0.236
Plasma TFV concentration (ng/mL) a 88.0 (67.0–102.5) 56.0 (50.5–60.5) 0.073
  1. BMI body mass index, BSA body surface area, eGFR estimated glomerular filtration rate, INSTIs integrase strand transfer inhibitors, TFV tenofovir
  2. aValues are reported as median (interquartile range)